| Citation: |
CHEN Jinbin, ZHANG Yaojun, CHEN Minshan. Current Status and Future of Multidisciplinary Team in Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2025, 52(6): 436-441. DOI: 10.3971/j.issn.1000-8578.2025.24.1303
|
Hepatocellular carcinoma (HCC) poses a significant hazard to public health in China because of its high incidence, high mortality, and high rate of advanced stages. Early detection and treatment of HCC by screening for high-risk populations is instrumental for enhancing survival rates among patients with HCC in China. Liver resection, local ablation, interventional therapy, radiotherapy, and drug therapy are all effective treatments for patients with HCC, and appropriate treatments can be selected based on different tumor stages. However, the condition of patients with HCC in China is complicated, and no single specialty offers the complete spectrum of care. The disease-centered multidisciplinary team for HCC is a crucial method to prolong the survival of patients with HCC and optimize their quality of life. Recent advancements in different disciplines have brought new opportunities in HCC treatments and altered multidisciplinary management approaches. Meanwhile, new challenges have emerged, and many problems have yet to be addressed.
Competing interests: The authors declare that they have no competing interests.
| [1] |
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263. doi: 10.3322/caac.21834
|
| [2] |
Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4(1): 47-53. doi: 10.1016/j.jncc.2024.01.006
|
| [3] |
Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2021, 7(1): 6. doi: 10.1038/s41572-020-00240-3
|
| [4] |
中国抗癌协会肝癌专业委员会. 中国肝癌多学科综合治疗专家共识[J]. 临床肝胆病杂志, 2021, 37(2): 278-285. [Chinese Society of Liver Cancer, Chinese Anti-Cancer Association. Chinese expert consensus on multidisciplinary treatment of liver cancer[J]. Lin Chuang Gan Dan Bing Za Zhi, 2021, 37(2): 278-285.]
Chinese Society of Liver Cancer, Chinese Anti-Cancer Association. Chinese expert consensus on multidisciplinary treatment of liver cancer[J]. Lin Chuang Gan Dan Bing Za Zhi, 2021, 37(2): 278-285.
|
| [5] |
Park JW, Chen M, Colombo M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study[J]. Liver Int, 2015, 35(9): 2155-2166. doi: 10.1111/liv.12818
|
| [6] |
中华医学会肝病学分会. 原发性肝癌二级预防共识(2021年版)[J]. 临床肝胆病杂志, 2021, 37(3): 532-542. [Chinese Society of Liver Cancer, Chinese Anti-Cancer Association. Chinese expert consensus on multidisciplinary treatment of liver cancer[J]. Lin Chuang Gan Dan Bing Za Zhi, 2021, 37(3): 532-542.]
Chinese Society of Liver Cancer, Chinese Anti-Cancer Association. Chinese expert consensus on multidisciplinary treatment of liver cancer[J]. Lin Chuang Gan Dan Bing Za Zhi, 2021, 37(3): 532-542.
|
| [7] |
Bruix J, Takayama T, Mazzaferro V, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial[J]. Lancet Oncol, 2015, 16(13): 1344-1354. doi: 10.1016/S1470-2045(15)00198-9
|
| [8] |
Li SH, Mei J, Cheng Y, et al. Postoperative Adjuvant Hepatic Arterial Infusion Chemotherapy With FOLFOX in Hepatocellular Carcinoma With Microvascular Invasion: A Multicenter, Phase Ⅲ, Randomized Study[J]. J Clin Oncol, 2023, 41(10): 1898-1908. doi: 10.1200/JCO.22.01142
|
| [9] |
Li QJ, He MK, Chen HW, et al. Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase Ⅲ Trial[J]. J Clin Oncol, 2022, 40(2): 150-160. doi: 10.1200/JCO.21.00608
|
| [10] |
Bi X, Zhao H, Zhao H, et al. Consensus of Chinese Experts on Neoadjuvant and Conversion Therapies for Hepatocellular Carcinoma: 2023 Update[J]. Liver Cancer, 2024, 14(2): 223-238.
|
| [11] |
Peng ZW, Lin XJ, Zhang YJ, et al. Radiofrequency ablation versus hepatic resection for the treatment of hepatocellular carcinomas 2 cm or smaller: a retrospective comparative study[J]. Radiology, 2012, 262(3): 1022-1033. doi: 10.1148/radiol.11110817
|
| [12] |
Peng ZW, Liu FR, Ye S, et al. Radiofrequency ablation versus open hepatic resection for elderly patients (> 65 years) with very early or early hepatocellular carcinoma[J]. Cancer, 2013, 119(21): 3812-3820. doi: 10.1002/cncr.28293
|
| [13] |
Takayama T, Hasegawa K, Izumi N, et al. Surgery versus Radiofrequency Ablation for Small Hepatocellular Carcinoma: A Randomized Controlled Trial (SURF Trial)[J]. Liver Cancer, 2021, 11(3): 209-218.
|
| [14] |
Peng ZW, Zhang YJ, Chen MS, et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial[J]. J Clin Oncol, 2013, 31(4): 426-432. doi: 10.1200/JCO.2012.42.9936
|
| [15] |
Qi X, Yang M, Ma L, et al. Synergizing sunitinib and radiofrequency ablation to treat hepatocellular cancer by triggering the antitumor immune response[J]. J Immunother Cancer, 2020, 8(2): e001038. doi: 10.1136/jitc-2020-001038
|
| [16] |
Yang Z, Liu S, Hu L, et al. Stereotactic body radiotherapy is an alternative to radiofrequency ablation for single HCC ≤5.0 cm[J]. JHEP Rep, 2024, 6(10): 101151. doi: 10.1016/j.jhepr.2024.101151
|
| [17] |
Wei X, Jiang Y, Zhang X, et al. Neoadjuvant Three-Dimensional Conformal Radiotherapy for Resectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Randomized, Open-Label, Multicenter Controlled Study[J]. J Clin Oncol, 2019, 37(24): 2141-2151. doi: 10.1200/JCO.18.02184
|
| [18] |
Xi M, Yang Z, Hu L, et al. Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Recurrent Small Hepatocellular Carcinoma: A Randomized, Open-Label, Controlled Trial[J]. J Clin Oncol, 2025, 43(9): 1073-1082. doi: 10.1200/JCO-24-01532
|
| [19] |
Li Z, Liu J, Zhang B, et al. Neoadjuvant tislelizumab plus stereotactic body radiotherapy and adjuvant tislelizumab in early-stage resectable hepatocellular carcinoma: the Notable-HCC phase 1b trial[J]. Nat Commun, 2024, 15(1): 3260. doi: 10.1038/s41467-024-47420-3
|
| [20] |
He M, Li Q, Zou R, et al. Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial[J]. JAMA Oncol, 2019, 5(7): 953-960. doi: 10.1001/jamaoncol.2019.0250
|
| [21] |
Lyu N, Wang X, Li JB, et al. Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase Ⅲ Trial (FOHAIC-1)[J]. J Clin Oncol, 2022, 40(5): 468-480. doi: 10.1200/JCO.21.01963
|
| [22] |
Li B, Qiu J, Zheng Y, et al. Conversion to Resectability Using Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy for Initially Unresectable Hepatocellular Carcinoma[J]. Ann Surg Open, 2021, 2(2): e057. doi: 10.1097/AS9.0000000000000057
|
| [23] |
Mehta N, Frenette C, Tabrizian P, et al. Downstaging Outcomes for Hepatocellular Carcinoma: Results From the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) Consortium[J]. Gastroenterology, 2021, 161(5): 1502-1512. doi: 10.1053/j.gastro.2021.07.033
|
| [24] |
Sarwar A, Malik MS, Vo NH, et al. Efficacy and Safety of Radiation Segmentectomy with (90)Y Resin Microspheres for Hepatocellular Carcinoma[J]. Radiology, 2024, 311(2): e231386. doi: 10.1148/radiol.231386
|
| [25] |
Qin S, Bai Y, Lim HY, et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia[J]. J Clin Oncol, 2013, 31(28): 3501-3508. doi: 10.1200/JCO.2012.44.5643
|
| [26] |
Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med, 2008, 359(4): 378-390. doi: 10.1056/NEJMoa0708857
|
| [27] |
Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial[J]. Lancet, 2018, 391(10126): 1163-1173. doi: 10.1016/S0140-6736(18)30207-1
|
| [28] |
Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2017, 389(10064): 56-66. doi: 10.1016/S0140-6736(16)32453-9
|
| [29] |
Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma[J]. N Engl J Med, 2018, 379(1): 54-63. doi: 10.1056/NEJMoa1717002
|
| [30] |
Zhu AX, Kang YK, Yen CJ, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2019, 20(2): 282-296. doi: 10.1016/S1470-2045(18)30937-9
|
| [31] |
Qin S, Bi F, Gu S, et al. Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase Ⅱ-Ⅲ Trial[J]. J Clin Oncol, 2021, 39(27): 3002-3011. doi: 10.1200/JCO.21.00163
|
| [32] |
Qin S, Li Q, Gu S, et al. Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial[J]. Lancet Gastroenterol Hepatol, 2021, 6(7): 559-568. doi: 10.1016/S2468-1253(21)00109-6
|
| [33] |
Qin S, Chan SL, Gu S, et al. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study[J]. Lancet, 2023, 402(10408): 1133-1146. doi: 10.1016/S0140-6736(23)00961-3
|
| [34] |
Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma[J]. N Engl J Med, 2020, 382(20): 1894-1905. doi: 10.1056/NEJMoa1915745
|
| [35] |
Ren Z, Xu J, Bai Y, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study[J]. Lancet Oncol, 2021, 22(7): 977-990. doi: 10.1016/S1470-2045(21)00252-7
|
| [36] |
Qin S, Kudo M, Meyer T, et al. Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Phase 3 Randomized Clinical Trial[J]. JAMA Oncol, 2023, 9(12): 1651-1659. doi: 10.1001/jamaoncol.2023.4003
|
| [37] |
Sangro B, Galle PR, Kelley RK, et al. Patient-Reported Outcomes From the Phase Ⅲ HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma[J]. J Clin Oncol, 2024, 42(23): 2790-2799. doi: 10.1200/JCO.23.01462
|
| [38] |
Qin S, Chen Z, Fang W, et al. Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase Ⅲ Trial[J]. J Clin Oncol, 2023, 41(7): 1434-1443. doi: 10.1200/JCO.22.00620
|
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: